

A preliminary short form prospectus dated November 14, 2017 (the “**Preliminary Prospectus**”) of Titan Medical Inc. (“**Titan**”) containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in the provinces of British Columbia, Alberta and Ontario. The Preliminary Prospectus is still subject to completion. A copy of the Preliminary Prospectus, and any amendment, is required to be delivered with this document. There will not be any sale or any acceptance of an offer to buy the securities of Titan until a receipt for the final short form prospectus has been issued. This presentation does not provide full disclosure of all material facts relating to the securities offered under the Preliminary Prospectus. Investors should read the Preliminary Prospectus, the final short form prospectus of Titan and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.



Investor Presentation

TSX: TMD | OTCQB: TITXF

November 14, 2017

Forward Looking Statements

This presentation contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, technological development and implementation, performance and business prospects, opportunities, and illustrations and prototypes of the SPORT™ Surgical Systems. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance, achievements or technological development and implementation to be materially different from any future results, performance, achievements or technological development and implementation that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form in respect of the fiscal year ended December 31, 2016 and other information contained in the Company's public filings (which may be viewed at www.sedar.com). Information contained in this presentation is qualified in its entirety by such public filings. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the presentation are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. This presentation does not constitute an offer to sell any class of securities of the Company in any jurisdiction.

Cautionary Note Regarding United States Securities Laws

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Titan, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of Titan have not been and will not be registered under the *United States Securities Act of 1933*, as amended (the "**U.S. Securities Act**"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons", as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.



Titan Medical Overview

Designer and developer of the **SPORT Surgical System**, a versatile single incision platform that is intended to address an underserved segment of the multibillion-dollar* market for abdominal surgeries performed using robotic technology.


Designed for improved clinical capabilities,
operating room efficiency and hospital economics.



*Global medical robotic systems market to reach \$17.9 billion in 2022, Market Analysis and Segment Forecasts to 2022, Grand View Research.



Evolution of Surgical Care



Today's Robotic Surgery Environment

Robotic technology was introduced to mitigate the risks of minimally invasive surgery (MIS), reduce variations in procedural efficiency and improve consistency of patient outcomes.

Primary Benefits:

- Increased Dexterity
- Better Visualization
- Improved Ergonomics



SPORT Surgical System

- Versatile single port robotic surgery solution
- Overcomes multi-port robotic surgery limitations
- Engineered for performance, efficiency and cost-effectiveness
- Provides access to underserved market segments



Technology Differentiation

Engineered for Simplicity and Efficiency



Single Incision

With a single incision made around the umbilicus, the result can be near scarless surgery



Small Footprint

Enhanced mobility and ease-of-use leads to quicker deployment in multiple ORs and higher utilization



Multi-Articulating

Single-use end-effectors on reusable multi-articulating instrument arms result in optimal and economical device performance in every procedure



Open Display

3D high definition display offers the perfect balance of surgical immersion and situational awareness in the OR



Ergonomic Workstation

Highly ergonomic workstation with natural handle interface enables comfortable surgical posture, even during long procedures



Purposeful Design

Designed from the ground up to improve:

- Clinical Capabilities**
- OR Efficiency**
- Hospital Economics**



SPORT Workstation




- Ergonomically focused design
- Natural multi-articulated handle interface
- Open, unobtrusive 3D high-definition display platform
- Easily maneuverable with swiveling easy-gliding casters



SPORT Patient Cart



- Single incision system
- Single-arm configuration
- Compact
- Rollers enable mobility
- Convenient to maneuver and position



SPORT CIT and Instruments




- Camera Insertion Tube (CIT) includes 3D camera, laser light source, and accommodates two multi-articulating instruments
- Variety of multi-use instruments with single patient use end effectors for suturing, grasping, cutting and coagulation



Single Incision
Surgery + Enhanced
Robotic Technology

Optimal Patient Care



SPORT provides surgeons with multi-articulated instruments through a single incision.




Intellectual Property

The SPORT Surgical System is a unique single incision robotic surgical system that has been developed based on clinical user requirements

18 Patents

46 Applications

Areas of the SPORT Surgical System covered by patents or pending applications:



Plan for Commercialization*

- 2017** ➤ Human factors, design, development and pre-clinical studies

- 2018** ➤ Development, tooling, pre-clinical studies, regulatory submission preparation and application

- 2019** ➤ Projected regulatory clearance and approvals, commercialization in U.S. and Europe

*Based on management's current estimates.




2017 Year-to-date Progress

- Recruited qualified VP of Research & Development, VP of Quality & Regulatory Affairs
- Assessed product development program, established 2017-2018 milestones
- Conducted surgeon interviews and demos on SPORT prototype
- Completed USD \$5 M March Canadian capital raise led by Bloom Burton Securities Inc.
- Resumed product development and human factors studies
- Finalized user requirements for 1st generation SPORT
- Issued Patents
 - U.S. Patent No. 9,629,688 titled “Actuator and Drive for Manipulating a Tool”
 - European Patent No. EP2996613, titled “Articulated Tool Positioner and System Employing Same”
- Completed USD \$7 M (approx.) June-July Canadian & U.S. capital raise
- Converted USD \$2 M deposit to equity held by Longtai Medical
- Established Centers of Excellence in U.S. and Europe for preclinical SPORT studies
- Successfully performed first preclinical studies with advanced SPORT prototype
- Completed USD \$2.7 M October surgeon-led private placement



Summary

- Addressing underserved segment of multibillion dollar global robotic surgery market
- Highly versatile, differentiated advanced single incision platform
- Substantial benefits to patients, surgeons and hospitals versus competitive offerings
- Engineered for clinical performance, operating room efficiency and hospital economics
- Attractive capital and recurring revenue model
- Experienced management team with record of success





Thank You

TSX: TMD | OTCQB: TITXF